US 11098103
CD80 extracellular domain polypeptides and their use in cancer treatment
granted A61KA61K2039/505A61K38/00
Quick answer
US patent 11098103 (CD80 extracellular domain polypeptides and their use in cancer treatment) held by Five Prime Therapeutics, Inc. expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K2039/505, A61K38/00, A61K38/1774, A61K39/39558